1. Home
  2. SNSE vs MBAI Comparison

SNSE vs MBAI Comparison

Compare SNSE & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sensei Biotherapeutics Inc.

SNSE

Sensei Biotherapeutics Inc.

HOLD

Current Price

$32.21

Market Cap

12.2M

Sector

Health Care

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

N/A

Current Price

$1.56

Market Cap

12.0M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SNSE
MBAI
Founded
2005
2004
Country
United States
Israel
Employees
N/A
85
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.2M
12.0M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SNSE
MBAI
Price
$32.21
$1.56
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
$65.00
N/A
AVG Volume (30 Days)
31.5K
115.1K
Earning Date
05-08-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.26
$1.31
52 Week High
$36.76
$3.92

Technical Indicators

Market Signals
Indicator
SNSE
MBAI
Relative Strength Index (RSI) 54.20 42.39
Support Level $7.94 $1.38
Resistance Level $35.94 $1.91
Average True Range (ATR) 2.70 0.17
MACD -0.04 -0.03
Stochastic Oscillator 64.24 13.92

Price Performance

Historical Comparison
SNSE
MBAI

About SNSE Sensei Biotherapeutics Inc.

Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: